Skip to main content

Tweets

JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P

Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago

Where there’s smoke, there’s flare: how pollution fuels RA The World Health Organisation (WHO) has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 (1, 2)… https://t.co/hmXPa492Qr https://t.co/BBClCplk8Z

Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
Health Literacy: the forgotten social determinant of health? Nine out of ten adults in the USA struggle to understand basic health-related information (1). Across the pond, in the UK, 7.1 million adults read at, or below, the level of a nine-year-old, with 60% unable to… https://t.co/15gvQxZHNN https://t.co/VqCjZY4tYI
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
ICYMI: Precision medicine in Ssc ILD? Yes! -Watch and wait approach can cause irreversible lung damage. -⬆️CRP: biomarker of response (predicts mortality) -⬆️KL-6: biomarker of severity (predicts progression of fibrosis) -FAPI-PET: can eval disease activity vs response to ttx.… https://t.co/bTepwrsuNN https://t.co/e6xjtuquka
Adela Castro @AdelaCastro222 ( View Tweet )
3 months 3 weeks ago
Beyond the Needle: Redefining the Assessment of Lupus Nephritis Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE). https://t.co/fvGG0BZbOL #ACR24 https://t.co/wPXQz9Vese
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
Cancer Survival in RA Dr. Eric Dein interviews Joshua Hsieh about abstract 0474, Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis, presented at #ACR24. https://t.co/2957Nq6Ajy https://t.co/3swVyigA3g
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
COVID Associated Immune Disease Dr. Len Calabrese reports on a session he participated in discussing if Covid-19 is associated or causal for autoimmune disease. Reporting from #ACR24 https://t.co/vFdlf9XVzf https://t.co/JhpglNVIt7
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
Finding the Right Combination Therapy in RA Dr. Jonathan Kay interviews Dr. Ernest Choy about abstract 0521, Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in RA, presented at… https://t.co/yPmDIZ6aKI https://t.co/cairKrbDDu
Dr. John Cush @RheumNow ( View Tweet )
3 months 3 weeks ago
RheumNow Day 4 Recap: ACR Convergence 2024 Highlights https://t.co/WvQB7y0bkm

Dr. John Cush @RheumNow ( View Tweet )

3 months 3 weeks ago
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush @RheumNow ( View Tweet )

3 months 3 weeks ago
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush @RheumNow ( View Tweet )

3 months 3 weeks ago
×